1)van Buskirk EM, Cioffi GA:Glaucomatous optic neuropathy. Am. J Ophthalmol 113:447-452, 1992
2)Jaenen N, Baudouin C, Pouliquen P et al:Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 17:341-349, 2007
3)Fechtner RD, Godfrey DG, Budenz D et al:Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 29:618-621, 2010
4)Lee SY, Wong TT, Chua J et al:Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolality. Eye(Lond)27:1142-1150, 2013
5)Jumblatt JE, Jumblatt MM:Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res 67:341-346, 1998
6)Murakami T, Fujihara T, Horibe Y et al:Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res 36:89-93, 2004
7)Fujihara T, Murakami T, Fujita H et al:Improvement of corneal barrier function by the P2Y(2)agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci 42:96-100, 2001
8)Martin-Gil A, de Lara MJ, Crooke A et al:Silencing of P2Y(2)receptors reduces intraocular pressure in New Zealand rabbits. Br J Pharmacol 165:1163-1172, 2012
9)Pintor J, Peral A, Pelāez T et al:Presence of diadenosine polyphosphates in the aqueous humor:their effect on intraocular pressure. J Pharmacol Exp Ther 304:342-348, 2003
10)日本緑内障学会緑内障診療ガイドライン作成委員会(編):緑内障診療ガイドライン(第3版),日眼会誌116:5-46,2012
11)ドライアイ研究会診療ガイドライン作成委員会:ドライアイ診療ガイドライン.日眼会誌123:489-592,2019
12)Schmidl D, Witkowska KJ, Kaya S et al:The association between subjective and objective parameters for the assessment of dry eye syndrome. Invest Ophthalmol Vis Sci 56:1467-1472, 2015
13)Bron AJ, Evans VE, Smith JA:Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22:640-650, 2003
14)Jin SW, Min JS:Clinical evaluation of the effect of diquafosol ophthalmic solution in glaucoma patients with dry eye syndrome. Jpn J Ophthalmol 60:150-155, 2016